WOBURN, Mass.--(BUSINESS WIRE)--March 30, 2006--ArQule, Inc. (Nasdaq: ARQL) today announced that data from its Phase 1 monotherapy trial with ARQ 501 in patients with advanced solid tumors will be presented in the late breaking session at the 97th Annual Meeting of the American Association for Cancer Research (AACR) in Washington, D.C.
